Showing 169–180 of 192 resultsSorted by latest
Pharma & Biotech
UnitedHealth Group continues to invest heavily in digital capabilities and artificial intelligence (AI) to enhance customer experiences, improve operational efficiencies, and drive productivity gains.
Regeneron Pharmaceuticals is facing heightened competition in the retinal disease and dermatology sectors, with the introduction of biosimilar alternatives like Lucentis and brolucizumab in the retinal category, and new JAK inhibitors challenging Dupixent in atopic dermatitis.
Johnson & Johnson faces competitive pressures and the loss of exclusivity for several key products, which could impact future revenue growth.
AbbVie’s flagship product, Humira, experienced a substantial operational revenue decline of 40.7% globally, with a full-year decrease of 31.9%.
CVS Healthcare Corp’s $5bn Settlement in Opioid Litigation: Opioid Litigation: In 2023, CVS agreed to pay approximately $5bn to settle lawsuits related to its role in the opioid crisis. The lawsuits alleged that CVS failed to properly monitor and report suspicious orders of prescription opioids, contributing to the nation’s opioid epidemic.
Eli Lilly and Company has recently intensified its commitment to research and development (R&D) activities, evident in a noteworthy 28% surge in R&D expenses. This substantial increase is attributed to the company’s strategic investments in both late-stage assets and early research projects, emphasizing its dedication to addressing unmet medical needs.
The challenges faced with AMG340 highlight the importance of diversifying and strengthening the product pipeline to mitigate risks associated with individual assets.
The company has witnessed a decline in sales of its hepatitis C virus (HCV) drug, particularly with a 1% year-over-year drop in Epclusa/authorized generics sales and a substantial 39% decrease in Harvoni/authorized generics sales.
Baxter International- The creation of Vantive may bring both opportunities and challenges. On the positive side, the increased focus on the kidney care segment could lead to specialized investments, potentially driving growth and innovation in that specific area.
AstraZeneca received approval for three new molecular entities Truqap, Wainua, and Voydeya demonstrating success in advancing its drug pipeline.
Medtronic faces a hefty tax hike from 8.3% in 2022 to 29.5% in 2023, impacting its bottom line. As Medtronic grapples with this heightened tax burden, its ability to adapt, strategize, and communicate effectively will play a pivotal role in determining how well it weathers this unexpected financial storm.
Danaher Corporation’s Escalating costs of sales have become a thorn in Danaher’s side, fueled by both inflationary pressures on raw materials and logistical headaches like exorbitant freight charges. These supply chain roadblocks hamper the company’s ability to stay competitive. Managing these rising costs while ensuring timely product delivery has become a constant juggling act, threatening Danaher’s edge in the market.